Papillary thyroid cancer and cutaneous melanoma: An often underrecognized pair.
作者信息
Chernyak Michelle, Hutchison Dana, Smith Janellen
机构信息
Department of Dermatology, University of California, Irvine, Irvine, California.
出版信息
JAAD Case Rep. 2024 May 28;50:22-24. doi: 10.1016/j.jdcr.2024.05.026. eCollection 2024 Aug.
Abstract
摘要
相似文献
1
Papillary thyroid cancer and cutaneous melanoma: An often underrecognized pair.甲状腺乳头状癌和皮肤黑色素瘤：一对常被忽视的组合。
JAAD Case Rep. 2024 May 28;50:22-24. doi: 10.1016/j.jdcr.2024.05.026. eCollection 2024 Aug.
2
Synchronous occurrence of medullary and papillary carcinoma of the thyroid in a patient with cutaneous melanoma: determination of BRAFV600E in peripheral blood and tissues. Report of a case and review of the literature.皮肤黑色素瘤患者甲状腺髓样癌与乳头状癌的同步发生：外周血和组织中BRAFV600E的检测。1例病例报告及文献复习
Endocr Pathol. 2014 Sep;25(3):324-31. doi: 10.1007/s12022-014-9303-1.
3
BRAF(V600E) mutation is not a positive predictor for distant metastasis in sporadic papillary thyroid carcinoma.BRAF(V600E) 突变并非散发性甲状腺乳头状癌远处转移的阳性预测因子。
Chin Med J (Engl). 2013 Aug;126(16):3013-8.
4
Langerhans cell histiocytosis and Erdheim-Chester disease, both with cutaneous presentations, and papillary thyroid carcinoma all harboring the BRAF(V600E) mutation.朗格汉斯细胞组织细胞增多症和埃尔德海姆-切斯特病均有皮肤表现，以及均携带BRAF（V600E）突变的乳头状甲状腺癌。
J Cutan Pathol. 2016 Mar;43(3):270-5. doi: 10.1111/cup.12636. Epub 2015 Nov 20.
5
[Correlation between BRAF mutation and aggressive biological behavior of papillary thyroid carcinoma].
Zhonghua Yi Xue Za Zhi. 2023 Apr 11;103(14):1060-1063. doi: 10.3760/cma.j.cn112137-20220729-01657.
6
Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.维莫非尼用于放射性碘难治性BRAF（V600E）阳性转移性或不可切除性乳头状甲状腺癌患者：一项非随机、多中心、开放标签的2期试验。
Lancet Oncol. 2016 Sep;17(9):1272-82. doi: 10.1016/S1470-2045(16)30166-8. Epub 2016 Jul 23.
7
Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas.高分化甲状腺癌皮肤转移灶的临床病理特征及BRAF（V600E）突变分析
Cancer. 2007 May 15;109(10):1965-71. doi: 10.1002/cncr.22641.
8
The prevalence and prognostic value of BRAF mutation in thyroid cancer.BRAF突变在甲状腺癌中的患病率及预后价值
Ann Surg. 2007 Sep;246(3):466-70; discussion 470-1. doi: 10.1097/SLA.0b013e318148563d.
9
Detection of BRAFV600E mutation on papillary thyroid carcinoma and metastatic malignant melanoma by fine-needle aspiration cytology: how genetic testing may drive toward personalized medicine.通过细针穿刺细胞学检测甲状腺乳头状癌和转移性恶性黑色素瘤中的BRAFV600E突变：基因检测如何推动个性化医疗。
Diagn Cytopathol. 2014 Oct;42(10):877-9. doi: 10.1002/dc.23060. Epub 2013 Nov 7.
10
[The co-relation of BRAF V600E mutation and factors affecting occurrence and prognosis of papillary thyroid carcinoma].[BRAF V600E突变与影响甲状腺乳头状癌发生及预后因素的相关性]
Zhonghua Bing Li Xue Za Zhi. 2019 Apr 8;48(4):288-292. doi: 10.3760/cma.j.issn.0529-5807.2019.04.005.
本文引用的文献
1
Papillary thyroid cancer organoids harboring BRAF mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies.具有 BRAF 突变的甲状腺乳头癌类器官揭示了基于 BRAF 抑制剂的联合疗法的潜在益处。
J Transl Med. 2023 Jan 9;21(1):9. doi: 10.1186/s12967-022-03848-z.
2
Papillary Thyroid Cancer Presenting with Incidental Skin Lesion: Critical Management of Distant Metastasis.以偶然发现的皮肤病变为表现的甲状腺乳头状癌：远处转移的关键管理
Sisli Etfal Hastan Tip Bul. 2022 Jun 28;56(2):299-302. doi: 10.14744/SEMB.2021.70846. eCollection 2022.
3
Pharmacological inhibition of Ref-1 enhances the therapeutic sensitivity of papillary thyroid carcinoma to vemurafenib.药理学抑制 Ref-1 增强了乳头状甲状腺癌对 vemurafenib 的治疗敏感性。
Cell Death Dis. 2022 Feb 8;13(2):124. doi: 10.1038/s41419-022-04550-0.
4
Melanoma and Thyroid Carcinoma: Our Current Understanding.黑色素瘤与甲状腺癌：我们当前的认识
J Clin Aesthet Dermatol. 2019 Sep;12(9):39-41. Epub 2019 Sep 1.
5
BRAF and epithelial-mesenchymal transition in primary cutaneous melanoma: a role for Snail and E-cadherin?BRAF与原发性皮肤黑色素瘤中的上皮-间质转化：Snail和E-钙黏蛋白的作用？
Hum Pathol. 2016 Jun;52:19-27. doi: 10.1016/j.humpath.2015.12.030. Epub 2016 Feb 1.
6
c-Met-mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition.c-Met介导的PI3K/AKT信号通路重新激活导致BRAF（V600E）突变型甲状腺癌对BRAF抑制不敏感。
Mol Carcinog. 2016 Nov;55(11):1678-1687. doi: 10.1002/mc.22418. Epub 2015 Oct 12.
7
Cutaneous metastasis of papillary thyroid carcinoma to the neck: a case report and review of the literature.甲状腺乳头状癌颈部皮肤转移：一例报告并文献复习
Dermatol Online J. 2014 Dec 13;21(2):13030/qt78v2d22d.
8
Increased melanoma risk in individuals with papillary thyroid carcinoma.患有甲状腺乳头癌的个体患黑色素瘤的风险增加。
JAMA Otolaryngol Head Neck Surg. 2014 May;140(5):423-7. doi: 10.1001/jamaoto.2014.78.
9
Induction of thyroid gene expression and radioiodine uptake in melanoma cells: novel therapeutic implications.黑色素瘤细胞中甲状腺基因表达的诱导及放射性碘摄取：新的治疗意义。
PLoS One. 2009 Jul 10;4(7):e6200. doi: 10.1371/journal.pone.0006200.
Zotero 插件